Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
17 oct. 2024 16h30 HE
|
Profound Medical Corp.
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
16 oct. 2024 16h15 HE
|
Profound Medical Corp.
– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final...
Profound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA
16 sept. 2024 08h00 HE
|
Profound Medical Corp.
- Educational event for physicians by physicians; participants heard from an esteemed panel of experts, innovators, and guest speakers - - Global medtech leaders, Siemens Healthineers and Cook...
Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference
04 sept. 2024 16h30 HE
|
Profound Medical Corp.
TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces Second Quarter 2024 Financial Results
08 août 2024 16h05 HE
|
Profound Medical Corp.
TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
18 juil. 2024 16h30 HE
|
Profound Medical Corp.
TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases
11 juil. 2024 07h00 HE
|
Profound Medical Corp.
TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Annual General Meeting of Shareholders Voting Results
15 mai 2024 17h00 HE
|
Profound Medical Corp.
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General Meeting of...
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
14 mai 2024 07h30 HE
|
Profound Medical Corp.
– Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 parameters extracted from 7,466 training images – – Validated in standalone and multi-reader,...
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
09 mai 2024 16h05 HE
|
Profound Medical Corp.
TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...